AiCuris Anti-infective Cures AG reported that pritelivir demonstrated superior complete lesion healing compared with investigator’s choice therapy in people living with HIV enrolled in the Phase 3 PRIOH-1 trial for refractory herpes simplex virus infection. In the subgroup analysis presented at the Conference on Retroviruses and Opportunistic Infections, 61 percent of participants receiving pritelivir achieved complete lesion healing within 28 days versus 20 percent in the comparator arm, with a statistically significant adjusted treatment difference in post-hoc analysis.

The importance of this update lies in the therapeutic gap it addresses rather than in the numerical difference alone. Refractory herpes simplex virus infection in people living with HIV represents a persistent clinical challenge, particularly when lesions fail to respond to standard nucleoside analogues or when resistance emerges. Although combination antiretroviral therapy has improved immune restoration for many patients, HSV remains more aggressive, prolonged, and atypical in immunocompromised hosts. Treatment failures often lead to intravenous salvage regimens that are toxic, logistically complex, and burdensome for both patients and care systems.

Why the PRIOH-1 HIV subgroup analysis signals a potential shift in managing clinically refractory HSV beyond acyclovir resistance

Within the PRIOH-1 population, individuals living with HIV accounted for more than one third of the immunocompromised cohort. Most of these participants met criteria for clinical refractoriness, defined by lack of improvement after at least seven days of antiviral therapy, and a subset had laboratory confirmed acyclovir resistance. This composition reflects real world infectious disease practice, where clinicians encounter both confirmed resistance and persistent non-response without always having genotypic data available.

The 61 percent complete lesion healing rate observed with pritelivir therefore suggests clinical utility that extends beyond narrowly defined resistance. For physicians managing complex HIV populations, an oral antiviral capable of resolving lesions that have failed standard therapy could reduce hospitalizations, shorten treatment duration, and improve quality of life. Industry observers note that lesion healing in this setting is not merely cosmetic but a marker of virologic control and symptom resolution in patients who often endure painful, chronic ulcerations that impair adherence to antiretroviral therapy and daily functioning.

However, the subgroup analysis was post-hoc and included a modest sample size. The confidence intervals around the treatment difference remain wide. While statistical significance was achieved, regulators will assess whether the magnitude of effect is consistent and reproducible across broader immunocompromised populations. The signal is compelling, but confirmatory interpretation rests on the totality of PRIOH-1 data and on how clearly the HIV subgroup mirrors outcomes in the full randomized cohort.

How helicase-primase inhibition with pritelivir could reshape antiviral resistance strategy in immunocompromised HIV populations

Pritelivir targets the viral helicase-primase complex, a mechanism distinct from nucleoside analogues such as acyclovir, valacyclovir, and famciclovir. Resistance to acyclovir typically arises from mutations affecting viral thymidine kinase or DNA polymerase, pathways that pritelivir does not rely upon. This mechanistic differentiation underpins its relevance in refractory and resistant HSV.

Clinicians tracking antiviral resistance patterns have long emphasized the need for agents that circumvent thymidine kinase dependence. In people living with HIV, repeated HSV recurrences and cumulative antiviral exposure create selective pressure that can erode efficacy of first-line therapies. An oral agent operating through a novel viral target introduces an alternative therapeutic axis that may delay or bypass classical resistance pathways.

Yet mechanistic novelty alone does not guarantee durable effectiveness. Observers will monitor whether widespread helicase-primase inhibition leads to new resistance mutations over time. Laboratory surveillance, viral sequencing data, and real world registries will be critical in determining whether pritelivir maintains its edge once deployed outside controlled trial environments.

What the open-label PRIOH-1 design and comparator heterogeneity mean for regulatory confidence and endpoint interpretation

PRIOH-1 was designed as a global, controlled, open-label comparative trial enrolling randomized immunocompromised patients with refractory or resistant HSV infection. The comparator arm reflected investigator’s choice therapy, including intravenous foscarnet, intravenous or topical cidofovir, and topical imiquimod. This pragmatic approach enhances real world applicability, as these agents represent the limited salvage options currently available.

However, the open-label nature of the study introduces potential bias, particularly when endpoints involve clinical assessment of lesion healing. While complete lesion closure is a relatively objective measure, assessment timing and investigator judgment can influence classification. Regulatory reviewers will scrutinize endpoint adjudication processes, consistency across study sites, and handling of missing data in order to assess robustness.

Safety data may ultimately carry significant weight in the benefit risk equation. Pritelivir was associated with fewer renal and electrolyte abnormalities compared with investigator’s choice therapy, which often includes nephrotoxic agents such as foscarnet. Treatment completion rates were markedly higher in the pritelivir arm. In a population already managing HIV infection and complex medication regimens, tolerability and convenience are not peripheral considerations but central determinants of adoption, adherence, and long-term outcomes.

What clinicians, regulators, and industry observers are likely to monitor before pritelivir can be integrated into HSV treatment guidelines

Regulators will assess whether the subgroup findings align with outcomes in other immunocompromised populations studied in PRIOH-1, including transplant recipients and patients with malignancies. Consistency of benefit across these groups would strengthen the case for approval in a defined refractory HSV indication and reduce concerns that the observed effect is confined to a small subset.

Clinicians will seek clarity on durability of response and recurrence rates beyond the 28 day treatment window. HSV in people living with HIV often follows a relapsing course. Data on sustained lesion resolution, viral shedding suppression, and prevention of new outbreaks will influence confidence in integrating pritelivir into treatment algorithms.

Drug interaction potential with antiretroviral therapy also warrants close examination. Although no major signals have been highlighted publicly, pharmacokinetic compatibility with commonly used integrase inhibitors, protease inhibitors, and non-nucleoside reverse transcriptase inhibitors will be essential for routine use. Even modest interaction risks could complicate uptake in heavily treated HIV populations.

From a health system perspective, reimbursement dynamics will shape uptake. Intravenous salvage therapies impose hospitalization costs and monitoring burdens. An effective oral alternative could be economically attractive if priced within acceptable thresholds. Payers and guideline committees will likely weigh direct drug costs against reductions in inpatient care, infusion infrastructure, and complication management.

Manufacturing capacity and global access represent additional variables. Refractory HSV in people living with HIV is a global issue, including in regions with high HIV prevalence and constrained healthcare resources. If pritelivir secures regulatory approval, equitable distribution strategies and alignment with international treatment guidelines will determine its public health impact.

The PRIOH-1 subgroup analysis shifts pritelivir from mechanistic promise to clinically demonstrated benefit in a high-need HIV-associated population. The data do not eliminate uncertainty, particularly given the post-hoc nature of the analysis, but they establish a signal strong enough to alter the competitive and regulatory conversation around refractory HSV therapy. For infectious disease specialists managing immunocompromised patients, the prospect of a safer, oral antiviral with superior lesion healing offers a meaningful advance in a field that has seen limited innovation in recent decades.

  acyclovir resistance, AiCuris Anti-infective Cures AG, antiviral therapy, herpes simplex virus, HIV, HSV, Phase 3 trial, PRIOH-1, pritelivir